Stock News

Intec Pharma Ltd. (NTEC) Reaches $4.20 Yearly Low; Heska (HSKA) Sentiment Is 0.92

Intec Pharma Ltd. (NASDAQ:NTEC) Logo

Heska Corp (HSKA) investors sentiment increased to 0.92 in 2018 Q1. It’s up 0.15, from 0.77 in 2017Q4. The ratio has improved, as 59 funds opened new and increased holdings, while 64 sold and decreased holdings in Heska Corp. The funds in our database now have: 6.05 million shares, up from 5.99 million shares in 2017Q4. Also, the number of funds holding Heska Corp in top ten holdings was flat from 0 to 0 for the same number . Sold All: 27 Reduced: 37 Increased: 40 New Position: 19.

The stock of Intec Pharma Ltd. (NASDAQ:NTEC) hit a new 52-week low and has $3.82 target or 9.00% below today’s $4.20 share price. The 6 months bearish chart indicates high risk for the $139.72M company. The 1-year low was reported on Jun, 16 by Barchart.com. If the $3.82 price target is reached, the company will be worth $12.57M less. The stock decreased 1.18% or $0.05 during the last trading session, reaching $4.2. About 206,233 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has declined 17.59% since June 16, 2017 and is downtrending. It has underperformed by 30.16% the S&P500. Some Historical NTEC News: ; 04/04/2018 – Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting; 11/04/2018 – Intec Pharma Announces Pricing of $35.4 M Public Offering of Ordinary Shrs; 11/04/2018 – INTEC PHARMA REPORTS PRICING OF $35.4M OFFERING OF ORDINARY; 09/03/2018 Intec Pharma 4Q Loss/Shr 39c; 03/04/2018 – Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson’s Disease; 26/03/2018 – Intec Pharma Names Roger J. Pomerantz to Board of Director; 15/05/2018 – Intec Pharma 1Q Loss/Shr 41c; 10/04/2018 – Intec Pharma Announces Proposed Public Offering of Ordinary Shrs; 24/04/2018 – Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting; 24/04/2018 – Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annua

Analysts await Intec Pharma Ltd. (NASDAQ:NTEC) to report earnings on August, 8. They expect $-0.30 earnings per share, up 36.17% or $0.17 from last year’s $-0.47 per share. After $-0.41 actual earnings per share reported by Intec Pharma Ltd. for the previous quarter, Wall Street now forecasts -26.83% EPS growth.

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. Oppenheimer initiated the shares of NTEC in report on Thursday, June 22 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Friday, September 11. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) earned “Buy” rating by Oppenheimer on Thursday, September 21. Roth Capital maintained the shares of NTEC in report on Thursday, August 10 with “Buy” rating. TH Capital initiated it with “Buy” rating and $9.50 target in Friday, September 11 report. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Thursday, November 16 by Oppenheimer. On Wednesday, September 16 the stock rating was initiated by Maxim Group with “Buy”. The firm earned “Buy” rating on Monday, July 24 by Roth Capital. The stock has “Buy” rating by Roth Capital on Thursday, August 3.

Another recent and important Intec Pharma Ltd. (NASDAQ:NTEC) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $139.72 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients.

More recent Heska Corporation (NASDAQ:HSKA) news were published by: Seekingalpha.com which released: “Heska: Pets Are People Too” on May 18, 2018. Also Benzinga.com published the news titled: “10 Biggest Price Target Changes For Friday” on June 15, 2018. Nasdaq.com‘s news article titled: “Recent Analysis Shows Alexander’s, American National Insurance, VAREX IMAGING, Banner, Instructure, and Heska …” with publication date: May 24, 2018 was also an interesting one.

Ratings analysis reveals 50% of Heska Corp’s analysts are positive. Out of 2 Wall Street analysts rating Heska Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. HSKA was included in 2 notes of analysts from November 29, 2016. The firm has “Buy” rating by Benchmark given on Tuesday, November 29. The firm earned “Neutral” rating on Thursday, January 26 by CL King.

Analysts await Heska Corporation (NASDAQ:HSKA) to report earnings on July, 30. They expect $0.17 earnings per share, down 61.36% or $0.27 from last year’s $0.44 per share. HSKA’s profit will be $1.27M for 156.63 P/E if the $0.17 EPS becomes a reality. After $0.28 actual earnings per share reported by Heska Corporation for the previous quarter, Wall Street now forecasts -39.29% negative EPS growth.

Tygh Capital Management Inc. holds 1.68% of its portfolio in Heska Corporation for 111,885 shares. Grace & White Inc Ny owns 81,210 shares or 1.32% of their US portfolio. Moreover, Grandeur Peak Global Advisors Llc has 1.06% invested in the company for 118,250 shares. The California-based Park West Asset Management Llc has invested 0.96% in the stock. Summit Creek Advisors Llc, a Minnesota-based fund reported 62,953 shares.

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company has market cap of $794.44 million. It operates through two divisions, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. It has a 109.47 P/E ratio. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps.

Heska Corporation (NASDAQ:HSKA) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *